

ISIS™
PHARMACEUTICALS

RECEIVED
CENTRAL FAX CENTER
MAR 15 2006

**Patent Department
1896 Rutherford Rd.
Carlsbad, CA 92008
Facsimile Information**

Date: March 15, 2006

Please deliver the following information to:

Name: Commissioner for Patents
Company: United States Patent & Trademark Office
Fax No.: (571) 273-8300
Re: ISPS-2000

We are transmitting 7 page(s), including this cover sheet

Comments:

Dear Sirs:

Please find attached a Request for Corrected Filing Receipt for application no. 10/657,600 filed 09/08/2003 previously faxed on January 31, 2005, which, according to PAIR, was not received.

Thank You,
Kemlyn Evans

This Fax is from

Name: Kemlyn Evans
Patent Administrator
Fax # (760) 603-3820 Telephone # (760) 603-2705
Transmitted by: Kemlyn

CONFIDENTIALITY NOTICE

The information in this facsimile message is legally privileged and confidential, and intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any unauthorized disclosure, copying, distribution or taking of any action in reliance on the contents of the telecopied materials is strictly prohibited and review by any individual other than the intended recipient shall not constitute waiver of the attorney client privilege. If you have received this transmission in error, please immediately notify us by telephone in order to arrange for the return of the materials.

Thank you.

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(To be used for all correspondence after initial filing)

Total Number of Pages In This Submission

Application Number	10/657,600
Filing Date	September 8, 2003
First Named Inventor	Ole Buchardt
Art Unit	1714
Examiner Name	Not Assigned
Attorney Docket Number	ISPS-2000

**RECEIVED
CENTRAL FAX CENTER**
MAR 15 2006

15

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Request for Corrected Filing Receipt
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Remarks	

counsel copied

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Isis Pharmaceuticals, Inc.		
Signature			
Printed name	Donna T. Ward		
Date	1-31-05	Reg. No.	48,271

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Laura Earnes	Date	1-31-05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT
ISPS-2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Buchardt, et al**)
Serial No.: **10/657,600**)
Filed: **September 8, 2003**)
Title: **PEPTIDE NUCLEIC ACIDS**)

Group Art Unit: **1714**)
Examiner: **Not Assigned**)

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:
January 31, 2005

RECEIVED
CENTRAL FAX CENTER
MAR 15 2006


Laura Eames

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attn: Office of Initial Patent Examination's
Filing Receipt Corrections

REQUEST TO CORRECTED FILING RECEIPT

Dear Sir:

Enclosed for your information is a copy of the Filing Receipt issued by the PTO with respect to the above-identified application. You will note that the following items require correction:

In the Applicant(s):

Please delete "Egholn" and insert therefor --Egholm--.

Since this appears to be an error on the part of the United States Patent and Trademark Office, it is respectfully requested that a corrected filing receipt be issued in this case.

Applicants additionally request that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Respectfully submitted,

ISIS Pharmaceuticals, Inc.
2292 Faraday Ave.
Carlsbad, CA 92008
(760) 931-9200

By:


Donna T. Ward
Registration No.: 48,271

January 31, 2005

BEST AVAILABLE COPYUNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/657,600	09/08/2003	1714	1782	ISPS-2000	31	68	5

CONFIRMATION NO. 2098

32650
 WOODCOCK WASHBURN LLP
 ONE LIBERTY PLACE - 46TH FLOOR
 PHILADELPHIA, PA 19103

F050EN12D

DEC 02 2004**UPDATED FILING RECEIPT**


OC000090014826091

Date Mailed: 11/29/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ole Buchardt, Varlose, DENMARK;
Egholm Michael Egholm, Frederiksberg, DENMARK;
 Peter Eigil Nielsen, Kokkedal, DENMARK;
 Rolf Henrik Berg, Frederiksberg, DENMARK;

**Power of Attorney:** The patent practitioners associated with Customer Number 32650**Domestic Priority data as claimed by applicant**

This application is a DIV of 08/468,719 06/06/1995 PAT 6,710,163
 which is a DIV of 08/108,591 11/22/1993 PAT 6,395,474

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) PCT/EP92/01219 05/01/1993
 DENMARK DK 0986/91 05/24/1991
 DENMARK DK 0987/91 05/24/1991
 DENMARK DK 0510/92 04/15/1992

If Required, Foreign Filing License Granted: 12/05/2003

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/657,600**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

Peptide nucleic acids

Preliminary Class

524

BEST AVAILABLE COPY

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

03/15/2006 14:58 FAX 7606033820
01/31/2005 14:42 FAX 7606033820

ISIS PATENT DEPT
ISIS-PHARMACEUTICALS

→ PATENT OFFICE

007/007
001

*** TX REPORT ***

TRANSMISSION OK

TX/RX NO 0581
RECIPIENT ADDRESS 917037469196
DESTINATION ID PTO-FILING RCPT
ST. TIME 01/31 14:41
TIME USE 01'30
PAGES SENT 5
RESULT OK

PTC/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(To be used for all correspondence after initial filing)

Total Number of Pages in This Submission **5**

Application Number	10/887,600
Filing Date	September 8, 2003
First Named Inventor	Ole Buchardt
Art Unit	1714
Examiner Name	Not Assigned
Attorney Docket Number	ISPS-2000

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <input type="checkbox"/> Request for Corrected Filing Receipt
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Information Disclosure Statement		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Isis Pharmaceuticals, Inc.		
Signature			
Printed name	Donna T. Ward		
Date	1-31-05	Reg. No.	48,271